SCHEMBL25317220

SCHEMBL25317220

CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(Cc5ccc(C(=O)O)cc5)CC4)cc3C2)c(OCc2ccccc2)cc1OCc1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AB1 P08238 5/20 0.54
HSP90AA1 P07900 3/20 0.54
HSP90B1 P14625 1/20 0.54
MAPK1 P28482 2/20 0.43
PKM P14618 1/20 0.43
KDM4E B2RXH2 2/20 0.43
LMNA P02545 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
TSHR P16473 1/20 0.43
HDAC1 Q13547 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
ABCB1 P08183 1/20 0.42
ABCG2 Q9UNQ0 1/20 0.42
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
TP53 P04637 1/20 0.41
FAAH O00519 1/20 0.40
HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25216919 0.96 HSP90AB1 (0.58) HSP90AB1HSP90AA1HSP90B1MAPK1PKM
SCHEMBL31503222 0.93 HSP90AA1 (0.52) HSP90AB1HSP90AA1HSP90B1MAPK1PKM
SCHEMBL25317145 0.93 HSP90AA1 (0.52) HSP90AB1HSP90AA1HSP90B1MAPK1PKM
SCHEMBL384471 0.92 HSP90AB1 (0.64) HSP90AB1HSP90AA1HSP90B1MAPK1KDM4E
SCHEMBL31363033 0.91 HSP90AB1 (0.55) HSP90AB1HSP90AA1HSP90B1MAPK1PKM
SCHEMBL25260723 0.89 HSP90AA1 (0.54) HSP90AB1HSP90AA1HSP90B1KDM4ELMNA
SCHEMBL16582202 0.89 HSP90AB1 (0.53) HSP90AB1HSP90AA1HSP90B1KDM4ELMNA
SCHEMBL30829338 0.89 HSP90AB1 (0.53) HSP90AB1HSP90AA1HSP90B1KDM4ELMNA
SCHEMBL382566 0.89 HSP90AB1 (0.46) HSP90AB1HSP90AA1GLRA1
Hydrochloric Acid SCHEMBL16569693 0.88 HSP90AB1 (0.52) HSP90AB1HSP90AA1HSP90B1KDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250136614-A1 2,7-SUBSTITUTED PYRROLO[2,1-F][1,2,4]TRIAZINE COMPOUND HAVING PROTEIN KINASE INHIBITORY ACTIVITY MAGICBULLETTHERAPEUTICS CO., LTD. (KR) 2025-05-01 US disclosed
EP-4442691-A1 2,7-SUBSTITUTED PYRROLO[2,1-F][1,2,4]TRIAZINE COMPOUND HAVING PROTEIN KINASE INHIBITORY ACTIVITY Magicbullettherapeutics Co., Ltd. (KR) 2024-10-09 EP disclosed
WO-2023140629-A1 2,7-SUBSTITUTED PYRROLO[2,1-F][1,2,4]TRIAZINE COMPOUND HAVING PROTEIN KINASE INHIBITORY ACTIVITY 닥터아이앤비(주) 2023-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250136614-A1 2,7-SUBSTITUTED PYRROLO[2,1-F][1,2,4]TRIAZINE COMPOUND HAVING PROTEIN KINASE INHIBITORY ACTIVITY STK25, MAP3K15, MAP3K5 HSP90AB1 1468/4885HSP90AA1 1399/4885HSP90B1 2214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.